Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
06/23/2008
Trade Name:
Aptivus
Generic Name or Proper Name (*):
tipranavir
Indications Studied:
Co-administered with ritonavir for combination antiretroviral in patients who are treatment-experienced and infected with HIV-1 strains resistant to more than one protease inhibitor
Label Changes Summary:
Extended indication from adults to children 2 years and older The risk-benefit has not been established in patients <2 years of age Dosing is based on body weight or body surface area not to exceed adult dose Aes are generally similar to those seen in adults however, rash was more frequent in pediatric patients than in adults; The frequency of rash through 48 weeks of treatment was 21%. Most rashes were mild and 5% were moderate. Overall 3% interrupted treatment due to rash Information on dose, Aes, PK parameters, lab abnormalities, and clinical study
Product Labeling:
Labeling
BPCA(B) and PREA(P):
B, P
Sponsor:
Boehringer Ingelheim
Pediatric Exclusivity Granted Date:
03/07/2008
NNPS:
FALSE'
Therapeutic Category:
Antiviral
-
-